Biotech

  • Semaglutide Injection Pen hands
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    As obesity M&A heats up, pharmas could get ‘blinded by opportunity’

    With companies racing to secure GLP-1-related assets, there may be risks for moving too fast.

    By Kelly Bilodeau • Sept. 29, 2025
  • Albert Bourla
    Image attribution tooltip
    Dominik Bindl via Getty Images
    Image attribution tooltip

    Can a multibillion-dollar deal put Pfizer in the obesity big leagues?

    After a couple failed attempts on its own, Pfizer is hitting the M&A gas to bring in candidates that could help it become a weight loss heavyweight.

    By • Sept. 25, 2025
  • digital pill Explore the Trendline➔
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Artificial intelligence & machine learning

    After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

    By PharmaVoice staff
  • Desks line a darkened medical laboratory in this stock image.
    Image attribution tooltip
    Sean Anthony Eddy via Getty Images
    Image attribution tooltip

    Why Xoma, a drug royalty firm, is hunting biotech ‘zombies’

    The collapse in value of many biotechs over the past few years has created an opportunity for specialists like Xoma to “do the right thing” for the ecosystem and liquidate them, its executives say.

    By Gwendolyn Wu • Sept. 25, 2025
  • hands syringes
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pharma’s next generation of blockbuster antibodies takes a ‘more is better’ approach

    Why multi-specific antibodies are seeing a fresh surge of industry buzz.

    By Kelly Bilodeau • Sept. 24, 2025
  • An illustration of a maze inside a brain to represent Alzheimer's.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A

    Lilly’s Alzheimer’s efforts depend on newer, better biomarkers and diagnostics

    The pharma giant’s R&D in Alzheimer’s didn’t end with last year’s Kisunla approval, and diagnostics could define where the company goes next.

    By • Sept. 23, 2025
  • FDA sign
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    3 FDA approval firsts that could be around the corner

    Several market-altering decisions are on the agency’s docket for the rest of 2025.

    By • Sept. 19, 2025
  • Valley
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Biotech’s VC slowdown forces young drugmakers to adapt in the ‘valley of death’

    Amid the sector’s long winter, startups are shifting gears to extend their cash runways.

    By • Sept. 17, 2025
  • A BioNTech logo hangs on the side of an office building.
    Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip

    Moderna and BioNTech pioneered mRNA vaccines. But who will make a mark in therapeutics?

    While mRNA changed the game in vaccines, leveraging the technology to develop treatments has been trickier to navigate.

    By Kelly Bilodeau • Sept. 15, 2025
  • clock syringe
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    4 years from clinic to approval — Precigen’s ‘unprecedented’ FDA nod and what comes next

    The company scored the first-ever approval to treat a potentially deadly infection leveraging its gene therapy platform.

    By • Sept. 12, 2025
  • A brain scan is seen on a computer screen in an empty medical laboratory.
    Image attribution tooltip
    Dragos Condrea via Getty Images
    Image attribution tooltip

    A new class of sleep drugs draws Wall Street’s attention

    Clinical trial data presented this weekend show drugs from Takeda, Alkermes and Eisai significantly helped people with narcolepsy, heralding a new era of sleep medicine.

    By Jacob Bell • Sept. 10, 2025
  • basel switzerland
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pharma’s new boomtown? Why drugmakers are setting up shop in a small Swiss city.

    While the EU and UK attempt to lure scientists with new financial incentives, Basel’s stable economy and emphasis on science remains a draw.

    By Alexandra Pecci • Sept. 10, 2025
  • Brain pipette
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A

    Can new Alzheimer’s tests help clear the way for the next generation of therapies?

    A tau-related blood test could offer more insight in early-disease pathology to the complicated Alzheimer’s disease space.

    By • Sept. 9, 2025
  • dwarfism
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Inside pharma’s race to deliver new treatments for dwarfism

    By targeting the underlying genetic mutation that drives the condition, researchers hope to increase height and address debilitating complications.

    By Kelly Bilodeau • Sept. 8, 2025
  • AI drug discovery
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    How AI advances will shape the drugmaker of the future

    An AI revolution is taking place, and leaders from tech to Big Pharma are forecasting what drugmakers of the future will look like.

    By • Sept. 2, 2025
  • Boxes of COVID-19 vaccines from Pfizer and Moderna sit side by side.
    Image attribution tooltip
    Joe Raedle via Getty Images
    Image attribution tooltip

    FDA approves updated COVID boosters, but narrows use

    In a post on X, HHS Secretary Robert F. Kennedy said the FDA has cleared vaccines from Pfizer, Moderna and Novavax for use in "high risk" individuals.

    By Delilah Alvarado • Updated Aug. 27, 2025
  • Psychedelic therapy brain
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    AbbVie dives back into the neuro pool with a $1.2B psychedelics play

    Following a major clinical failure last year, AbbVie’s purchase of a psychedelic depression treatment has the potential to revive a touch-and-go market.

    By • Aug. 26, 2025
  • FDA
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Why an FDA decision for a new drug could ripple through the ultra-rare disease space

    All eyes are on Stealth BioTherapeutics as it awaits a long-delayed approval for its first-in-class treatment for Barth syndrome.

    By Alexandra Pecci • Aug. 26, 2025
  • Gilead sign
    Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    And just like that... pharma’s breakups reveal pain points in cancer R&D

    Biotech tie-ups with Gilead, Genetech and Ipsen that have recently been let go.

    By • Aug. 22, 2025
  • Frozen pharma vaccine
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A

    In cell therapy, cost is a hot issue. The industry might need a cold solution.

    The logistical linchpin of cryopreservation could make a challenging space more accessible.

    By • Aug. 19, 2025
  • Layofdfs
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Biopharma layoffs rise as drugmakers tighten belts and reorganize

    Contrary to a predicted slowdown, 2025’s layoffs are outpacing 2024.

    By Kelly Bilodeau • Aug. 18, 2025
  • Vaccine
    Image attribution tooltip
    Alex Wong via Getty Images
    Image attribution tooltip

    With scrapped mRNA funding, a vaccine maker finds a silver lining

    While mRNA is suffering the brunt of the MAHA movement with $500 million in funding cuts, other vaccine makers could fill some of that void.

    By • Aug. 14, 2025
  • Puerto Rico flag
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Puerto Rico’s ongoing journey from manufacturing hub to innovation enterprise

    Biotechs are coming to the island as tariffs threaten overseas drug exports, and finding Puerto Rico is more than just a leading manufacturing hub.  

    By • Aug. 12, 2025
  • stem cell treatment
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Are stem cell therapies ready for pharma’s prime time?

    Stem cell therapies are thriving on the fringes of healthcare — but science-backed treatments are also poised to make an impact in pharma R&D.

    By Kelly Bilodeau • Aug. 11, 2025
  • A man in a collared shirt poses for a photograph.
    Image attribution tooltip
    Permission granted by Vertex Pharmaceuticals
    Image attribution tooltip

    David Altshuler, geneticist who helped transform Vertex, to retire next year

    Since becoming Vertex's top scientist in 2015, Altshuler has helped the company become an industry powerhouse. He’ll depart next year in a “planned transition.”

    By Ben Fidler • Aug. 5, 2025
  • Stephane Bancel, Moderna
    Image attribution tooltip
    Chip Somodevilla / Staff via Getty Images
    Image attribution tooltip

    Let’s make a deal? Big Pharma execs express varying views on their M&A future

    Pharma executives are keeping their eyes open for dealmaking opportunities as every company has its own battles to fight.

    By • Aug. 5, 2025